Podcast to Discuss Therapy Management for Patients with Metastatic Renal Cell Carcinoma Receiving First-Line Axitinib Plus an Immune Checkpoint Inhibitor

Adis Journal Podcasts

This podcast covers topics including the metastatic renal cell carcinoma landscape with a focus on immune-oncology (IO) agents and tyrosine kinase inhibitors, axitinib indication (combination and monotherapy), a summary of efficacy and safety data, dose modification guidelines, and author experience of managing patients with the most common adverse events (AEs) encompassing prior to initiating therapy, patient education, and follow-up.

This podcast is published open access in Advances in Therapy and is fully citeable. You can access the original published podcast article through the Advances in Therapywebsite and by using this link: https://link.springer.com/article/10.1007/s12325-023-02513-1. All conflicts of interest can be found online.

Open Access This podcast is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The material in this podcast is included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

This podcast in intended for medical professionals.